1392 EVOLVE-104, a novel ULBP2-targeted T cell engager that integrates CD2 costimulation for the treatment of basal and squamous lineage tumors

التفاصيل البيبلوغرافية
العنوان:	1392 EVOLVE-104, a novel ULBP2-targeted T cell engager that integrates CD2 costimulation for the treatment of basal and squamous lineage tumors
المؤلفون:	Jay S Fine, Louis Matis, Stella Martomo, Xingyue An, Mohosin Sarkar, Abudukadier Abulizi, Guixian Jin, Evelyn Teran, Danielle Klaskin, Maria Hackett, Hayden Karp, Julio Rodriguez, Sonali Dhindwal, Changqing Yuan, Zengzu Lai, Jennifer Zeiger, Amber Fearnley, Oksana A Sergeeva, Eric M Tam, Tracy Lichter, Jeremy S Myers
المصدر:	Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
بيانات النشر:	BMJ Publishing Group
سنة النشر:	2023
المجموعة:	Directory of Open Access Journals: DOAJ Articles
مصطلحات موضوعية:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
نوع الوثيقة:	article in journal/newspaper
اللغة:	English
تدمد:	2051-1426
Relation:	https://doaj.org/toc/2051-1426; https://doaj.org/article/26c6651b0b594272bbdce220e09fc635
DOI:	10.1136/jitc-2023-SITC2023.1392
الاتاحة:	https://doi.org/10.1136/jitc-2023-SITC2023.1392 https://doaj.org/article/26c6651b0b594272bbdce220e09fc635
رقم الانضمام:	edsbas.1C15F828
قاعدة البيانات:	BASE

الوصف
تدمد:	20511426
DOI:	10.1136/jitc-2023-SITC2023.1392